Teva, Sanofi say bowel disease drug met primary targets
Israel’s Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn’s disease showed it had met primary goals.
Israel’s Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn’s disease showed it had met primary goals.
Guest Editors Raya Kheirbek, MD, FGSA, University of Maryland, Baltimore (Health Sciences Section) Markus Schafer, PhD, FGSA, Baylor University (Social Science
Walk 30 minutes daily to reduce stress, sleep well, and improve your mood.
Major supplier damaged by Hurricane Helene continues to bring production lines back online
A robotic hand uses fingertip sensors and AI to determine how firmly to grip before closing in on an object, overcoming a persistent problem for…
A spotlight on a few inspirational people doing amazing things in their 80s, 90s, and beyond
VERITAS supports the robust benefit of endovascular therapy in patients with vertebrobasilar artery occlusion with moderate to severe symptoms, with approximately 2·5-times increased likelihood of…
A Regina woman currently waiting for a kidney transplant is now seeking a donor through a social media post.
The impact of private equity investments in healthcare under the new administration is multifaceted. While deregulation and business-friendly policies could stimulate investment and drive innovation,…
One exposure has been reported in Montreal, two in Laval, and a dozen sites have been identified in the Laurentians.
Don’t forget about old hard drives and neglected Facebook accounts